<div id="readability-page-1"><div>                     <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/renovorx-inc-logo-1200x675.png/query-dj0yMDIxMTIwMzA5MTc0Ng?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/renovorx-inc-logo-1200x675.png/query-dj0yMDIxMTIwMzA5MTc0Ng"/>RenovoRx, Inc. (NASDAQ:RNXT - Get Free Report) insider Ramtin Agah acquired 12,000 shares of the firm's stock in a transaction dated Tuesday, December 16th. The shares were purchased at an average price of $0.85 per share, with a total value of $10,200.00. Following the acquisition, the insider owned 778,460 shares of the company's stock, valued at approximately $661,691. This represents a 1.57% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink.</p><p>Ramtin Agah also recently made the following trade(s): </p><ul><li>On Friday, December 5th, Ramtin Agah bought 10,000 shares of RenovoRx stock. The stock was purchased at an average price of $0.96 per share, for a total transaction of $9,600.00. </li><li>On Monday, November 24th, Ramtin Agah purchased 12,000 shares of RenovoRx stock. The shares were acquired at an average price of $0.80 per share, with a total value of $9,600.00. </li><li>On Friday, November 21st, Ramtin Agah acquired 10,000 shares of RenovoRx stock. The shares were acquired at an average price of $0.80 per share, for a total transaction of $8,000.00. </li></ul><h2>RenovoRx Stock Performance</h2><p>Shares of RenovoRx stock traded up $0.02 during trading hours on Thursday, reaching $0.89. The company's stock had a trading volume of 9,053 shares, compared to its average volume of 272,032. RenovoRx, Inc. has a one year low of $0.70 and a one year high of $1.69. The company has a market capitalization of $32.55 million, a P/E ratio of -2.43 and a beta of 1.30. The stock's fifty day simple moving average is $0.99 and its two-hundred day simple moving average is $1.15. </p><hr/><hr/><p>RenovoRx (NASDAQ:RNXT - Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $0.27 million during the quarter, compared to the consensus estimate of $0.41 million. RenovoRx had a negative net margin of 1,196.66% and a negative return on equity of 122.19%.  As a group, research analysts forecast that  RenovoRx, Inc. will post -0.4 earnings per share for the current year. </p><h2>Institutional Trading of RenovoRx</h2><p>Hedge funds have recently bought and sold shares of the business. Corsair Capital Management L.P. bought a new stake in shares of  RenovoRx during the 1st quarter worth $186,000.  Alyeska Investment Group L.P. purchased a new position in  RenovoRx in the 1st quarter valued at approximately $682,000.  HighTower Advisors LLC bought a new stake in shares of  RenovoRx during the 1st quarter valued at $40,000.  ADAR1 Capital Management LLC increased its position in shares of  RenovoRx by 143.3% during the first quarter. ADAR1 Capital Management LLC now owns 479,883 shares of the company's stock valued at $475,000 after buying an additional 282,633 shares during the period.  Finally, AWM Investment Company Inc. purchased a new stake in shares of  RenovoRx in the first quarter worth about $2,262,000. 3.10% of the stock is currently owned by institutional investors. </p><h2>Wall Street Analysts Forecast Growth</h2><p>RNXT has been the topic of several analyst reports. Ascendiant Capital Markets lifted their target price on RenovoRx from $12.00 to $12.50 and gave the company a &#34;buy&#34; rating in a research report on Friday, November 21st. Weiss Ratings  restated a &#34;sell (e+)&#34; rating on shares of RenovoRx in a research note on Monday. Finally, Wall Street Zen downgraded shares of RenovoRx from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, October 25th. Two equities research analysts have rated the stock with a Buy rating and one  has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Hold&#34; and an average price target of $7.75.</p><p><b>Read Our Latest Report on RNXT</b></p><h2>RenovoRx Company Profile</h2><p> (Get Free Report)</p><p>RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.</p><h2>See Also</h2><ul><li>Five stocks we like better than RenovoRx</li><li>How to Effectively Use the MarketBeat Ratings Screener</li><li>3 Cheap Dividend Stocks That Can Beat Inflation and Pay You to Wait</li><li>What is the NASDAQ Stock Exchange?</li><li>3 New Year’s Resolution Stocks That Could Turn Around in 2026</li><li>What is a Stock Market Index and How Do You Use Them?</li><li>Cannabis Stocks Up for Reversal: Pipedreams or Opportunity?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Uk5YVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Uk5YVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].</em></p>                     <div>                         <p>Insider Buying or Selling at RenovoRx?</p>                         <p>Sign-up to receive InsiderTrades.com's daily insider buying and selling report for RenovoRx and related companies.</p>                                                                       </div>                                                               <div>                         <p>From Our Partners</p><div><div><p><img src="https://imageproxy.pbkrs.com/https://s3.amazonaws.com/iores/16939bffe4faa3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="704" height="392" original-src="https://imageproxy.pbkrs.com/https://s3.amazonaws.com/iores/16939bffe4faa3"/></p><div><p>ECGS Prepares for Nasdaq Uplisting and Why to Pay Attention Now.</p><p>A lesser-known consumer brand is quietly scaling a premium bottled water platform with ambitions beyond its re...</p><p><span>Interactive Offers</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjc0MQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjc0MQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20250716114931_image.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1100" height="733" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20250716114931_image.png"/></p><div><p>BNZI Posts Record Q3 Revenue – See What’s Driving It.</p><p>As AI dominates headlines, one lesser-known company is quietly scaling real-world applications in marketing te...</p><p><span>Huge Alerts</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjczOQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjczOQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251126070338_pushainewer-14.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251126070338_pushainewer-14.jpg"/></p><div><p>Buy this $2 Gold Stock Before January 1, 2026</p><p>You need to own this company now - before the company’s scheduled production begins.</p><p><span>Golden Portfolio</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjU3NA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjU3NA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/20251014140916_unnamed.png/query-MTc2MDQ2ODk1OTIxOA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="512" height="288" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/20251014140916_unnamed.png/query-MTc2MDQ2ODk1OTIxOA"/></p><div><p>Do not delete, read immediately</p><p>You can feel it — something in the economy has shifted. The headlines say everything’s fine, but the rising co...</p><p><span>Porter &amp; Company</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjUxMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjUxMw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251107163807_pushbusiness-1730089640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251107163807_pushbusiness-1730089640.jpg"/></p><div><p>[How To] Claim Your Pre-IPO Stake In SpaceX!</p><p>For the first time ever, James Altucher – one of America’s top venture capitalists – is sharing how ANYONE can...</p><p><span>Paradigm Press</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQxMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQxMQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://marketingassets.marketwise.com/prod/images/brownstoneresearch/et/2025/10_Oct/2510_BNF_Helium_3_Spad_6.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="500" height="500" original-src="https://imageproxy.pbkrs.com/https://marketingassets.marketwise.com/prod/images/brownstoneresearch/et/2025/10_Oct/2510_BNF_Helium_3_Spad_6.jpg"/></p><div><p>Forget AI, This Will Be the Next Big Tech Breakthrough</p><p>After picking Nvidia in 2016, before it jumped 27,000%...  Jeff Brown is back with what he believes will be ...</p><p><span>Brownstone Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQwMg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQwMg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251009102123_pushbitcoin-3089728640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251009102123_pushbitcoin-3089728640.jpg"/></p><div><p>Bitcoin is down but your income is about to explode</p><p>Bitcoin just dipped, and while most people are staring at the price, they’re missing the real opportunity — th...</p><p><span>Investors Alley</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjIyMg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjIyMg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251211115908_pushthumbsup.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251211115908_pushthumbsup.png"/></p><div><p>Companies Forced to Hand Over 90% of Profits</p><p>Why Is Nobody Talking About What Just Happened at Mar-a-Lago?  He served on one of Trump's top advisory boar...</p><p><span>Wide Moat Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjY2Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjY2Mg"/></p></div></div></div>                     </div>                 </div></div>

RNXT

<p>RenovoRx insider Ramtin Agah purchased 12,000 shares at $0.85 each, totaling $10,200, increasing his ownership by 1.57% to 778,460 shares. The transaction was disclosed in an SEC filing. RenovoRx's stock performance shows a trading price of $0.89, with a market cap of $32.55 million. Analysts have mixed ratings, with a consensus "Hold" and a target price of $7.75. RenovoRx is a clinical-stage biopharmaceutical company focusing on cancer therapies.</p>

RenovoRx (NASDAQ:RNXT) Insider Ramtin Agah Purchases 12,000 Shares